- Home
- RCS vs ACIU Comparison
RCS vs ACIU Comparison
Compare RCS & ACIU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RCS | ACIU |
|---|---|---|
| Founded | 1994 | 2003 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 251.8M | 288.0M |
| IPO Year | N/A | 2015 |
Fundamental Metrics
Financial Performance| Metric | RCS | ACIU |
|---|---|---|
| Price | $5.28 | $2.79 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $10.00 |
| AVG Volume (30 Days) | 155.6K | ★ 248.0K |
| Earning Date | 01-01-0001 | 05-12-2026 |
| Dividend Yield | ★ 10.12% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $706.75 |
| Revenue Next Year | N/A | $321.13 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.09 | $1.60 |
| 52 Week High | $8.00 | $4.00 |
Technical Indicators
Market Signals| Indicator | RCS | ACIU |
|---|---|---|
| Relative Strength Index (RSI) | 43.51 | 41.49 |
| Support Level | $5.09 | $2.58 |
| Resistance Level | $5.68 | $3.20 |
| Average True Range (ATR) | 0.12 | 0.16 |
| MACD | -0.02 | -0.02 |
| Stochastic Oscillator | 12.50 | 21.00 |
Price Performance
Historical ComparisonAbout RCS PIMCO Strategic Income Fund Inc.
PIMCO Strategic Income Fund, Inc. operates as a closed-end management investment company. Its primary investment objective is to generate a level of income that is higher than that generated by high-quality, intermediate-term U.S. debt securities. The Fund also seeks capital appreciation to the extent consistent with the objective.
About ACIU AC Immune SA
AC Immune SA is a clinical stage biopharmaceutical company advancing a portfolio of programs strategically focused on pioneering Precision Medicine for neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The company has one segment. The company currently focuses mostly of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.